NMTC (NeuroOne Medical Technologies) 5-Year EBITDA Growth Rate: 36.10% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NMTC NeuroOne Medical Technologies Corp NMTC
21 GF Score
Price $1.56
! 3 Warning Signs
View Full Analysis

What is NeuroOne Medical Technologies 5-Year EBITDA Growth Rate?

NeuroOne Medical Technologies NMTC -3.11% 21 5-Year EBITDA Growth Rate is 36.10% as of Jun. 2026. GuruFocus rates NMTC with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

NeuroOne Medical Technologies's EBITDA per Share for the three months ended in Jun. 2026 was $-0.22.

During the past 3 years, the average EBITDA Per Share Growth Rate was 50.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 36.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of NeuroOne Medical Technologies was 50.50% per year. The lowest was -337.80% per year. And the median was -6.80% per year.

NeuroOne Medical Technologies  (NAS:NMTC) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

NeuroOne Medical Technologies 5-Year EBITDA Growth Rate Related Terms

NMTC vs PMI, HSCS, IRIX: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, NeuroOne Medical Technologies's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroOne Medical Technologies 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's 5-Year EBITDA Growth Rate falls into.


NMTC
21GF Score
NeuroOne Medical Technologies Corp NMTC
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroOne Medical Technologies 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 36.10% mean?
NeuroOne Medical Technologies (NMTC) has a 5-Year EBITDA Growth Rate of 36.10% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for NeuroOne Medical Technologies and its competitors.
Is NeuroOne Medical Technologies' 5-Year EBITDA Growth Rate too high?
NeuroOne Medical Technologies' current 5-Year EBITDA Growth Rate is 36.10%. Overall, NeuroOne Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' 5-Year EBITDA Growth Rate compare to PMI and HSCS?
NeuroOne Medical Technologies' 5-Year EBITDA Growth Rate of 36.10% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for NeuroOne Medical Technologies and its competitors. NeuroOne Medical Technologies's current 5-Year EBITDA Growth Rate is 36.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
NeuroOne Medical Technologies (NMTC) has a current 5-Year EBITDA Growth Rate of 36.10%. The current 5-Year EBITDA Growth Rate is 36.10%. NeuroOne Medical Technologies' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current 5-Year EBITDA Growth Rate is 36.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroOne Medical Technologies Business Description

Address 7599 Anagram Drive, Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
21GF Score

Get the complete analysis for NMTC

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.56
Price